Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Fletcher

Showing results (1401-1410 of 1,501) with videos related to

Pageof 151
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 3, 2016
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapyE Ben-Ami, C M Barysauskas, M von Mehren, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 21, 2011
Aberrant AKT activation drives well-differentiated liposarcomaAlejandro Gutierrez, Eric L Snyder, Adrian Marino-Enriquez, et al.
Pediatric Obesity|February 1, 2019
Associations of sleep patterns with metabolic syndrome indices, body composition, and energy intake in children and adolescentsSarah J Mi, Nichole R Kelly, Robert J Brychta, et al.
The New England Journal of Medicine|April 4, 2014
Thyroid hormone inactivation in gastrointestinal stromal tumorsMichelle A Maynard, Adrian Marino-Enriquez, Jonathan A Fletcher, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 6, 2019
A Test-and-Not-Treat Strategy for Onchocerciasis Elimination in Loa loa-coendemic Areas: Cost Analysis of a Pilot in the Soa Health District, CameroonEdeltraud J Lenk, Henri C Moungui, Michel Boussinesq, et al.
Oncotarget|June 6, 2014
Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumorsChun-Nan Yeh, Chueh-Chuan Yen, Yen-Yang Chen, et al.
British Journal of Cancer|February 23, 2019
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumoursCésar Serrano, Adrián Mariño-Enríquez, Derrick L Tao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failureGeorge D Demetri, Michael C Heinrich, Jonathan A Fletcher, et al.
Molecular Cancer Therapeutics|July 17, 2019
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage StrategyThomas Mühlenberg, Julia Ketzer, Michael C Heinrich, et al.
Cell Metabolism|March 6, 2024
Hepatic malonyl-CoA synthesis restrains gluconeogenesis by suppressing fat oxidation, pyruvate carboxylation, and amino acid availabilityStanislaw Deja, Justin A Fletcher, Chai-Wan Kim, et al.
Pageof 151

Showing results (1401-1410 of 1,501) with videos related to

Sort By:
Pageof 151
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 3, 2016
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapyE Ben-Ami, C M Barysauskas, M von Mehren, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 21, 2011
Aberrant AKT activation drives well-differentiated liposarcomaAlejandro Gutierrez, Eric L Snyder, Adrian Marino-Enriquez, et al.
Pediatric Obesity|February 1, 2019
Associations of sleep patterns with metabolic syndrome indices, body composition, and energy intake in children and adolescentsSarah J Mi, Nichole R Kelly, Robert J Brychta, et al.
The New England Journal of Medicine|April 4, 2014
Thyroid hormone inactivation in gastrointestinal stromal tumorsMichelle A Maynard, Adrian Marino-Enriquez, Jonathan A Fletcher, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 6, 2019
A Test-and-Not-Treat Strategy for Onchocerciasis Elimination in Loa loa-coendemic Areas: Cost Analysis of a Pilot in the Soa Health District, CameroonEdeltraud J Lenk, Henri C Moungui, Michel Boussinesq, et al.
Oncotarget|June 6, 2014
Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumorsChun-Nan Yeh, Chueh-Chuan Yen, Yen-Yang Chen, et al.
British Journal of Cancer|February 23, 2019
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumoursCésar Serrano, Adrián Mariño-Enríquez, Derrick L Tao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failureGeorge D Demetri, Michael C Heinrich, Jonathan A Fletcher, et al.
Molecular Cancer Therapeutics|July 17, 2019
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage StrategyThomas Mühlenberg, Julia Ketzer, Michael C Heinrich, et al.
Cell Metabolism|March 6, 2024
Hepatic malonyl-CoA synthesis restrains gluconeogenesis by suppressing fat oxidation, pyruvate carboxylation, and amino acid availabilityStanislaw Deja, Justin A Fletcher, Chai-Wan Kim, et al.
Pageof 151